Influence of study characteristics on harm estimates from randomised controlled trials in patients with inflammatory arthritis receiving biological or synthetic antirheumatic drugs: a meta-epidemiological studyJohannes Iuel Berg, Sabrina Mai Nielsen, Esben Malm, John P A Ioannidis, Daniel E Furst, Josef S Smolen, Peter C Taylor, Lars Erik Kristensen, Simon Tarp, Torkell Ellingsen, Robin Christensen
8 November 2024
Dynamics of the gut microbiome in individuals at risk of rheumatoid arthritis: a cross-sectional and longitudinal observational studyChristopher M Rooney, Ian B Jeffery, Kulveer Mankia, Mark H Wilcox, Paul Emery
8 November 2024
Results from the international collaborative systematic literature review informing the 2023 EULAR recommendations for the treatment of systemic sclerosisAlain Lescoat, Eugenia Bertoldo, Jelena Čolić, Tania Santiago, Yossra A Suliman, Jenny Emmel, Philip G Conaghan, Yannick Allanore, Francesco del Galdo
7 November 2024
Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo-controlled, double-blind trialAdeline Ruyssen-Witrand, Clara Brusq, Maëva Masson, Vanina Bongard, Carine Salliot, Lucile Poiroux, Minh Nguyen, Christian Hubert Roux, Christophe Richez, Alain Saraux, Pascale Vergne-Salle, Jacques Morel, René-Marc Flipo, Muriel Piperno, Jacques-Eric GottenbergSee the full list of authors
29 October 2024
Imaging mass cytometry-based characterisation of fibroblast subsets and their cellular niches in systemic sclerosisAleix Rius Rigau, Minrui Liang, Veda Devakumar, Ranjana Neelagar, Alexandru-Emil Matei, Andrea-Hermina Györfi, Christina Bergmann, Tim Filla, Vladyslav Fedorchenko, Georg Schett, Jörg H W Distler, Yi-Nan Li
23 October 2024
Stratification according to autoantibody status in systemic sclerosis reveals distinct molecular signaturesBénedicte Rouvière, Christelle Le Dantec, Eleonore Bettacchioli, Lorenzo Beretta, Nathan Foulquier, Celine Cao, Christophe Jamin, Jacques-Olivier Pers, Martin Kerick, Javier Martin, on behalf of PRECISESADS Clinical Consortium, on behalf of PRECISESADS Metabolomic Study Group, Marta Eugenia Alarcón-Riquelme, Claire de Moreuil, Divi CornecSee the full list of authors
22 October 2024
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatmentEugen Feist, Roy M Fleischmann, Saeed Fatenejad, Daria Bukhanova, Sergey Grishin, Sofia Kuzkina, Michael Luggen, Evgeniy Nasonov, Mikhail Samsonov, Josef S Smolen
2 July 2024
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE studyCynthia Aranow, Cornelia F Allaart, Zahir Amoura, Ian N Bruce, Patricia C Cagnoli, Walter W Chatham, Kenneth L Clark, Richard Furie, James Groark, Murray B Urowitz, Ronald van Vollenhoven, Mark Daniels, Norma Lynn Fox, Yun Irene Gregan, Robert B HendersonSee the full list of authors
19 August 2024
Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendationsMyrto Kostopoulou, Chetan B Mukhtyar, George Bertsias, Dimitrios T Boumpas, Antonis Fanouriakis
22 May 2024
From fibrositis to fibromyalgia to nociplastic pain: how rheumatology helped get us here and where do we go from here?Daniel J Clauw
6 August 2024